METHODS: Forty-nine dogs with spontaneously occurring osteosarcoma underwent limb-sparing surgery after preoperative therapy consisting of intra-arterial cisplatin alone or intra-arterial cisplatin in combination with doses of radiation from 20-40 Gy in 10 fractions. All resections were marginal, and the defect was repaired with a cortical allograft. RESULTS: Local tumor control was strongly influenced by the percent necrosis in the excised specimen. Overall, the estimated 1-year local recurrence rate was approximately 32% (by life-table estimate). Dogs with less than 75% necrosis had an estimated 1-year recurrence rate of 65%; those with greater than 75% necrosis had an estimated 1-year recurrence rate of 15% (P = 0.004, by log-rank test). Local recurrence was influenced by the radiation dose. Dogs receiving 28 Gy or less had an estimated 50% 1-year recurrence rate, and those receiving 32 Gy or more had an estimated 8% 1-year recurrence rate (P = 0.03, by log-rank test). Normal host bone more frequently became necrotic at doses of 36 Gy or more. CONCLUSIONS: Intra-arterial cisplatin in combination with moderate doses of radiation (32 Gy) can achieve a high percent tumor necrosis while maintaining host bone viability. Survival was limited by distant metastasis but was lengthened by treatment compared with some earlier findings.
METHODS: Forty-nine dogs with spontaneously occurring osteosarcoma underwent limb-sparing surgery after preoperative therapy consisting of intra-arterial cisplatin alone or intra-arterial cisplatin in combination with doses of radiation from 20-40 Gy in 10 fractions. All resections were marginal, and the defect was repaired with a cortical allograft. RESULTS: Local tumor control was strongly influenced by the percent necrosis in the excised specimen. Overall, the estimated 1-year local recurrence rate was approximately 32% (by life-table estimate). Dogs with less than 75% necrosis had an estimated 1-year recurrence rate of 65%; those with greater than 75% necrosis had an estimated 1-year recurrence rate of 15% (P = 0.004, by log-rank test). Local recurrence was influenced by the radiation dose. Dogs receiving 28 Gy or less had an estimated 50% 1-year recurrence rate, and those receiving 32 Gy or more had an estimated 8% 1-year recurrence rate (P = 0.03, by log-rank test). Normal host bone more frequently became necrotic at doses of 36 Gy or more. CONCLUSIONS: Intra-arterial cisplatin in combination with moderate doses of radiation (32 Gy) can achieve a high percent tumornecrosis while maintaining host bone viability. Survival was limited by distant metastasis but was lengthened by treatment compared with some earlier findings.
Authors: Brennan Decker; Heidi G Parker; Deepika Dhawan; Erika M Kwon; Eric Karlins; Brian W Davis; José A Ramos-Vara; Patty L Bonney; Elizabeth A McNiel; Deborah W Knapp; Elaine A Ostrander Journal: Mol Cancer Res Date: 2015-03-12 Impact factor: 5.852
Authors: Amir Kol; Boaz Arzi; Kyriacos A Athanasiou; Diana L Farmer; Jan A Nolta; Robert B Rebhun; Xinbin Chen; Leigh G Griffiths; Frank J M Verstraete; Christopher J Murphy; Dori L Borjesson Journal: Sci Transl Med Date: 2015-10-07 Impact factor: 17.956
Authors: Rachel O Venable; Deanna R Worley; Daniel L Gustafson; Ryan J Hansen; E J Ehrhart; Shuang Cai; Mark S Cohen; M Laird Forrest Journal: Am J Vet Res Date: 2012-12 Impact factor: 1.156
Authors: Melinda Mata; Juan F Vera; Claudia Gerken; Cliona M Rooney; Tasha Miller; Catherine Pfent; Lisa L Wang; Heather M Wilson-Robles; Stephen Gottschalk Journal: J Immunother Date: 2014-10 Impact factor: 4.456
Authors: Melissa C Paoloni; Anita Tandle; Christina Mazcko; Engy Hanna; Stefan Kachala; Amy Leblanc; Shelley Newman; David Vail; Carolyn Henry; Douglas Thamm; Karin Sorenmo; Amin Hajitou; Renata Pasqualini; Wadih Arap; Chand Khanna; Steven K Libutti Journal: PLoS One Date: 2009-03-30 Impact factor: 3.240